Valion Bio Engages U.S. Defense Officials on Entolimod for Radiation Syndrome Treatment
Valion Bio, Inc. (Nasdaq: VBIO), a leading company in the field of innate immunotherapeutics, has made headlines with its latest discussions regarding Entolimod, a groundbreaking treatment for acute radiation syndrome (ARS). On May 14, 2026, Valion Bio conducted a significant joint briefing with senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA). This marked Valion Bio's second engagement in a month with the Department of War, following a previous presentation at the Pentagon on April 28, 2026.
The discussions centered on the need for a differentiated medical countermeasure against the threats posed by radiation exposure. Notably, there was a keen interest in developing an oral formulation of Entolimod. Such a formulation would enhance operational deployment options over traditional injectable treatments, particularly in situations involving mass casualties, thereby supporting broader strategies for emergency response among the military and national stockpile.
Michael K. Handley, the Chief Executive Officer of Valion Bio, emphasized the significance of this cross-agency engagement, stating, "The increasing interest in Entolimod reflects its strategic importance as a dual-tissue countermeasure against radiation. The focus on an oral formulation highlights the operational considerations necessary for field deployment and readiness of our national resources."
Entolimod functions as a novel Toll-like receptor 5 (TLR5) agonist, a mechanism that activates essential signaling pathways to stimulate bone marrow recovery and protect gastrointestinal tissues from radiation damage. This dual mechanism sets it apart from currently stocked countermeasures, such as Neupogen® and Neulasta®, which primarily address only hematopoietic recovery. Given the often critical role of gastrointestinal integrity in survival rates post-exposure, Entolimod could significantly improve outcomes in high-radiation scenarios.
As Valion Bio continues to advance its mission with over $140 million invested in the Entolimod program— bolstered by approximately $35.6 million in non-dilutive government funding—the company is also preparing for the transition toward a Biologics License Application under the FDA's Animal Rule. Their extensive research has included various studies involving non-human primates, yielding promising results in safety and efficacy, and involving around 300 human subjects.
The current geopolitical landscape prioritizes national security, with a pronounced emphasis on radiological preparedness. This reality is reflected in the heightened discussions and collaborations between Valion Bio and multiple U.S. government entities, further affirming the need for effective countermeasures against radiological threats.
"Our goal is straightforward—to secure acknowledgment and support for Entolimod at the necessary levels to ensure mass casualty and military applications are met with sufficient resources, thereby realizing its potential within our national defense capabilities," added Handley.
In conclusion, Valion Bio's ongoing dialogue with critical government agencies signifies a crucial step not only in medical innovation but also in enhancing national preparedness for future radiological incidents. With Entolimod positioned as a promising candidate for acute radiation syndrome treatment, the combined efforts and financial backing speak volumes about the importance of advancing solutions for public health and safety.
For more details on Valion Bio and Entolimod, visit the official website: www.valionbio.com.
The discussions centered on the need for a differentiated medical countermeasure against the threats posed by radiation exposure. Notably, there was a keen interest in developing an oral formulation of Entolimod. Such a formulation would enhance operational deployment options over traditional injectable treatments, particularly in situations involving mass casualties, thereby supporting broader strategies for emergency response among the military and national stockpile.
Michael K. Handley, the Chief Executive Officer of Valion Bio, emphasized the significance of this cross-agency engagement, stating, "The increasing interest in Entolimod reflects its strategic importance as a dual-tissue countermeasure against radiation. The focus on an oral formulation highlights the operational considerations necessary for field deployment and readiness of our national resources."
Entolimod functions as a novel Toll-like receptor 5 (TLR5) agonist, a mechanism that activates essential signaling pathways to stimulate bone marrow recovery and protect gastrointestinal tissues from radiation damage. This dual mechanism sets it apart from currently stocked countermeasures, such as Neupogen® and Neulasta®, which primarily address only hematopoietic recovery. Given the often critical role of gastrointestinal integrity in survival rates post-exposure, Entolimod could significantly improve outcomes in high-radiation scenarios.
As Valion Bio continues to advance its mission with over $140 million invested in the Entolimod program— bolstered by approximately $35.6 million in non-dilutive government funding—the company is also preparing for the transition toward a Biologics License Application under the FDA's Animal Rule. Their extensive research has included various studies involving non-human primates, yielding promising results in safety and efficacy, and involving around 300 human subjects.
The current geopolitical landscape prioritizes national security, with a pronounced emphasis on radiological preparedness. This reality is reflected in the heightened discussions and collaborations between Valion Bio and multiple U.S. government entities, further affirming the need for effective countermeasures against radiological threats.
"Our goal is straightforward—to secure acknowledgment and support for Entolimod at the necessary levels to ensure mass casualty and military applications are met with sufficient resources, thereby realizing its potential within our national defense capabilities," added Handley.
In conclusion, Valion Bio's ongoing dialogue with critical government agencies signifies a crucial step not only in medical innovation but also in enhancing national preparedness for future radiological incidents. With Entolimod positioned as a promising candidate for acute radiation syndrome treatment, the combined efforts and financial backing speak volumes about the importance of advancing solutions for public health and safety.
For more details on Valion Bio and Entolimod, visit the official website: www.valionbio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.